394 related articles for article (PubMed ID: 22927039)
21. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: challenges and solutions 2014.
Schönermarck U; Csernok E; Gross WL
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i46-52. PubMed ID: 25540095
[TBL] [Abstract][Full Text] [Related]
22. Antineutrophil cytoplasmic antibodies, autoimmune neutropenia, and vasculitis.
Grayson PC; Sloan JM; Niles JL; Monach PA; Merkel PA
Semin Arthritis Rheum; 2011 Dec; 41(3):424-33. PubMed ID: 21507463
[TBL] [Abstract][Full Text] [Related]
23. HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study.
Hilhorst M; Arndt F; Joseph Kemna M; Wieczorek S; Donner Y; Wilde B; Thomas Epplen J; van Paassen P; Cohen Tervaert JW
Arthritis Rheumatol; 2016 Jul; 68(7):1721-30. PubMed ID: 26866715
[TBL] [Abstract][Full Text] [Related]
24. Recent pathogenetic advances in ANCA-associated vasculitis.
Pendergraft WF; Nachman PH
Presse Med; 2015 Jun; 44(6 Pt 2):e223-9. PubMed ID: 26033562
[TBL] [Abstract][Full Text] [Related]
25. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis.
Li W; Huang H; Cai M; Yuan T; Sheng Y
Front Immunol; 2021; 12():624848. PubMed ID: 33841406
[TBL] [Abstract][Full Text] [Related]
26. Do ANCA-associated vasculitides and IgG4-related disease really overlap or not?
Erden A; Bolek EC; Yardimci KG; Kilic L; Bilgen SA; Karadag O
Int J Rheum Dis; 2019 Oct; 22(10):1926-1932. PubMed ID: 31571413
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.
Noone D; Hebert D; Licht C
Pediatr Nephrol; 2018 Jan; 33(1):1-11. PubMed ID: 27596099
[TBL] [Abstract][Full Text] [Related]
28. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go?
Kallenberg CG
Clin Exp Immunol; 2011 May; 164 Suppl 1(Suppl 1):1-3. PubMed ID: 21447120
[TBL] [Abstract][Full Text] [Related]
29. Dysregulated neutrophil--endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention.
Hu N; Westra J; Kallenberg CG
Autoimmun Rev; 2011 Jul; 10(9):536-43. PubMed ID: 21513817
[TBL] [Abstract][Full Text] [Related]
30. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides.
Csernok E
Autoimmun Rev; 2003 May; 2(3):158-64. PubMed ID: 12848957
[TBL] [Abstract][Full Text] [Related]
31. Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
Postgrad Med J; 2014 May; 90(1063):290-6. PubMed ID: 24737903
[TBL] [Abstract][Full Text] [Related]
32. Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis.
Tadema H; Kallenberg CG; Stegeman CA; Heeringa P
PLoS One; 2011 Mar; 6(3):e17972. PubMed ID: 21437233
[TBL] [Abstract][Full Text] [Related]
33. [Review article: Antineutrophil cytoplasmic antibody in small vessel vasculitis].
Nakano H; Ozaki S
Rinsho Byori; 2010 May; 58(5):480-9. PubMed ID: 20560457
[TBL] [Abstract][Full Text] [Related]
34. Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation.
Ohlsson S; Holm L; Hansson C; Ohlsson SM; Gunnarsson L; Pettersson Å; Skattum L
PLoS One; 2019; 14(6):e0218272. PubMed ID: 31216309
[TBL] [Abstract][Full Text] [Related]
35. Immune regulatory mechanisms in ANCA-associated vasculitides.
Lepse N; Abdulahad WH; Kallenberg CG; Heeringa P
Autoimmun Rev; 2011 Dec; 11(2):77-83. PubMed ID: 21856453
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis.
Nakazawa D; Masuda S; Tomaru U; Ishizu A
Nat Rev Rheumatol; 2019 Feb; 15(2):91-101. PubMed ID: 30542206
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of ANCA-associated vasculitis: An update.
Jarrot PA; Kaplanski G
Autoimmun Rev; 2016 Jul; 15(7):704-13. PubMed ID: 26970490
[TBL] [Abstract][Full Text] [Related]
38. [Pathophysiology of ANCA-associated vasculitides].
Mouthon L; Millet A; Régent A; Pederzoli-Ribeil M; Witko-Sarsat V
Presse Med; 2012 Oct; 41(10):996-1003. PubMed ID: 22921085
[TBL] [Abstract][Full Text] [Related]
39. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
Ann Rheum Dis; 2013 Aug; 72(8):1273-9. PubMed ID: 23606701
[TBL] [Abstract][Full Text] [Related]
40. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA.
Kraaij T; Kamerling SWA; van Dam LS; Bakker JA; Bajema IM; Page T; Brunini F; Pusey CD; Toes REM; Scherer HU; Rabelink TJ; van Kooten C; Teng YKO
Kidney Int; 2018 Jul; 94(1):139-149. PubMed ID: 29606398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
